levofloxacin has been researched along with Pulmonary Consumption in 62 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (4.84) | 18.2507 |
2000's | 18 (29.03) | 29.6817 |
2010's | 32 (51.61) | 24.3611 |
2020's | 9 (14.52) | 2.80 |
Authors | Studies |
---|---|
Boom, WH; Dietze, R; Hadad, DJ; Johnson, JL; Molino, LP; Palaci, M; Peloquin, CA | 1 |
Chi, Z; Pan, X; Tang, W; Yin, Y; Zhao, M | 1 |
He, Y; Li, X | 1 |
Beresneva, AE; Kononova, TE; Novitsky, VV; Serebryakova, VA; Urazova, OI; Vasil'eva, OA; Vengerovskii, AI | 1 |
Behr, MA; Benedetti, A; Britton, WJ; Dowdy, DW; Fox, GJ; Graham, SM; Marais, BJ; Marks, GB; Mason, P; Menzies, D; Nguyen, BH; Nguyen, CB; Nguyen, TA; Nguyen, VN; Tran, PT; Velen, K | 1 |
Huo, F; Li, Y; Liang, Q; Ma, Y; Pang, Y; Shang, Y; Xue, Y; Zhang, F; Zhao, L | 1 |
Dong, L; Huo, F; Li, S; Li, Y; Ma, Y; Pang, Y; Shang, Y; Xue, Y | 1 |
E R, V; Keny, S; Lawande, D; Parrikar, A | 1 |
Qiujing, F; Weiwei, W | 1 |
Kawkitinarong, K; Laohapojanart, N; Ratanajamit, C; Srichana, T | 1 |
Bate, PNN; Chiwala, G; Fang, C; Guan, P; Hameed, HMA; Hu, J; Khan, SA; Liu, J; Liu, Z; Mugweru, JN; Tan, S; Tan, Y; Wang, B; Yusuf, B; Zhang, T; Zhong, N | 1 |
Du, J; Gao, J; Gao, M; Li, L; Liu, Y; Ma, L; Mi, F; Tang, S; Zhang, Y | 1 |
Bouton, TC; Butler, D; Diacon, AH; Dianis, N; Eisenach, K; Gandhi, NR; Gotuzzo, E; Horsburgh, CR; Hunt, KR; Lecca, L; Martel, B; Mitnick, CD; Moreno-Martinez, A; Patientia, RF; Peloquin, CA; Phillips, PPJ; Santillan, J; Seas, C; Vargas, D; von Groote-Bidlingmaier, F | 1 |
Ahmad, N; Ahuja, SD; Akkerman, OW; Alffenaar, JC; Anderson, LF; Baghaei, P; Bang, D; Barry, PM; Bastos, ML; Behera, D; Benedetti, A; Bisson, GP; Boeree, MJ; Bonnet, M; Brode, SK; Brust, JCM; Cai, Y; Caumes, E; Cegielski, JP; Centis, R; Chan, ED; Chan, PC; Chang, KC; Charles, M; Cirule, A; D'Ambrosio, L; Dalcolmo, MP; de Vries, G; Dheda, K; Esmail, A; Flood, J; Fox, GJ; Fréchet-Jachym, M; Fregona, G; Gayoso, R; Gegia, M; Gler, MT; Gu, S; Guglielmetti, L; Holtz, TH; Hughes, J; Isaakidis, P; Jarlsberg, L; Kempker, RR; Keshavjee, S; Khan, FA; Kipiani, M; Koenig, SP; Koh, WJ; Kritski, A; Kuksa, L; Kvasnovsky, CL; Kwak, N; Lan, Z; Lange, C; Laniado-Laborín, R; Lee, M; Leimane, V; Leung, CC; Leung, EC; Li, PZ; Lowenthal, P; Maciel, EL; Marks, SM; Mase, S; Mbuagbaw, L; Menzies, D; Migliori, GB; Milanov, V; Miller, AC; Mitnick, CD; Modongo, C; Mohr, E; Monedero, I; Nahid, P; Ndjeka, N; O'Donnell, MR; Padayatchi, N; Palmero, D; Pape, JW; Podewils, LJ; Reynolds, I; Riekstina, V; Robert, J; Rodriguez, M; Schnippel, K; Seaworth, B; Seung, KJ; Shim, TS; Singla, R; Smith, SE; Sotgiu, G; Sukhbaatar, G; Tabarsi, P; Tiberi, S; Trajman, A; Trieu, L; Udwadia, ZF; van der Werf, TS; Veziris, N; Viiklepp, P; Vilbrun, SC; Walsh, K; Westenhouse, J; Yew, WW; Yim, JJ; Zetola, NM; Zignol, M | 1 |
Alffenaar, JC; Heysell, SK; Migliori, GB; Mpagama, S; Peloquin, CA; Skrahina, A; Sturkenboom, MGG; Touw, DJ; van den Elsen, SHJ; van der Werf, TS; Van't Boveneind-Vrubleuskaya, N | 1 |
Kononova, TE; Novitsky, VV; Serebryakova, VA; Urazova, OI; Vengerovskii, AI | 1 |
Bendet, P; Deshpande, D; Gumbo, T; Heysell, SK; Koeuth, T; Lee, PS; Mpagama, SG; Pasipanodya, JG; Srivastava, S | 1 |
Ambrose, PG; Bendet, P; Bhavnani, SM; Deshpande, D; Gumbo, T; Heysell, SK; Koeuth, T; Lee, PS; Mpagama, SG; Pasipanodya, JG; Srivastava, S; Thwaites, G | 1 |
Alffenaar, JWC; Kosterink, JGW; Pranger, AD; van der Werf, TS | 1 |
Akagawa, S; Ishida, M; Kawashima, M; Matsui, H; Nagai, H; Ota, K; Shimada, M; Suzuki, J; Tamura, A; Yamane, A | 1 |
Ahn, H; Ahn, JH; Cho, SN; Hahn, S; Jang, JY; Jeon, D; Jhun, BW; Jo, KW; Kang, YA; Kim, CK; Kim, DK; Kim, JS; Kim, SY; Kim, YR; Koh, WJ; Lee, JH; Lee, JY; Lee, M; Lee, SH; Lee, T; Mok, J; Park, JS; Shim, TS; Shin, S; Shin, SJ; Song, T; Won, HJ; Yim, JJ | 1 |
Ahmed, S; Al-Shaer, MH; Alghamdi, WA; Alkabab, Y; Alsultan, A; An, G; Banu, S; Barbakadze, K; Cegielski, JP; Heysell, SK; Houpt, E; Kempker, RR; Kipiani, M; Mikiashvili, L; Peloquin, CA | 1 |
Ahmed, I; Hasan, R; Inayat, R; Jabeen, K | 1 |
Davies, GR; Titarenko, AF; Ziganshina, LE | 1 |
Chan Kim, K; Choi, JC; Choi, SB; Choi, WI; Heo, EY; Hwang, YI; Jang, SH; Jeon, K; Jung, KH; Kang, YA; Ki, YW; Kim, KU; Kim, SJ; Kim, YH; Koh, WJ; Kwon, YS; Lee, CH; Lee, J; Lee, JH; Lee, SH; Lee, YS; Ryu, YJ; Shim, TS; Um, S; Yim, JJ; Yoo, KH | 1 |
Schluger, NW | 1 |
Gratz, J; Heysell, SK; Houpt, ER; Kibiki, GS; Kumburu, H; Mpagama, SG; Ndusilo, N; Peloquin, CA; Stroup, S | 1 |
Anzai, M; Ikeda, N; Katsube, O; Kikkawa, Y; Nomura, Y; Numao, T; Takizawa, H | 1 |
Araujo, MC; dos Santos, UM; Fachinelli, LR; Martins, RR; Modesto dos Santos, V; Ribeiro, KD | 1 |
Bharti, H; Bhushan, B; Chander, R; Gupta, A; Kajal, NC; Ranga, V | 1 |
Alsultan, A; An, G; Peloquin, CA | 1 |
Lee, CH; Lee, LN; Lee, MC; Wang, JT; Wang, JY; Yu, MC | 1 |
Babarina, MB; Sokolova, VI; Sychev, DA; Zaikov, DA | 1 |
Huh, HJ; Jeon, K; Jeong, BH; Koh, WJ; Lee, H; Lee, NY; Park, HY | 1 |
Baboolal, SO; Garcia-Prats, AJ; Hesseling, AC; Mohamed, N; Schaaf, HS; Solomons, R; van der Laan, LE; van Toorn, R; Willemse, M | 1 |
Chaiprasert, A; Disratthakit, A; Doi, N; Leechawengwongs, M; Prammananan, T; Thaipisuttikul, I; Tribuddharat, C | 1 |
Chen, S; Dong, L; Huang, H; Köser, CU; Moradigaravand, D; Parkhill, J; Peacock, SJ; Schön, T; Shang, Y; Wang, G; Wei, G; Yu, X | 1 |
Kunichan, AD; Lazareva, IaV; Sokolova, GB | 1 |
Chen, XC; Gou, JZ; Li, MZ; Peng, YZ; Tang, ZJ; Tong, XD; Yue, XH; Zhou, BP | 1 |
Yin, X; Yu, Z | 1 |
Hagiwara, E; Komatsu, S; Ogura, T; Sawahata, M; Sekine, A; Takahashi, H; Tsuchiya, N | 1 |
Akagawa, S; Ariga, H; Kaneko, Y; Kawabe, Y; Kawashima, M; Kunogi, M; Machida, K; Masuda, K; Matsui, H; Matsui, Y; Nagai, H; Nagayama, N; Nakajima, Y; Ohshima, N; Shimada, M; Suzuki, J; Tamura, A; Toyota, E | 1 |
Kato, S; Kobashi, Y; Mouri, K; Obase, Y; Oka, M | 1 |
Bukatina, AA; Galkina, KY; Isaeva, YD; Makarova, MV; Moroz, AM; Nosova, EY | 1 |
Covi, M; Fabbri, LM; Ferrara, G; Franco, F; Meschiari, E; Richeldi, L; Vailati, P; Velluti, G | 1 |
Istomin, EA; Mokrousov, IV; Narvskaia, OV; Otten, TF; Vishnevskiĭ, BI | 1 |
Chen, L; Chen, QL; Yin, JJ | 1 |
Gao, WW; Huang, XR; Ma, Y; Pan, YX; Wang, SM; Zhang, XX | 1 |
Li, SM; Xing, BC; Zheng, XM | 1 |
Desmond, EP; Nieda, RR; Sanders, CA | 1 |
Li, JH; Wang, YZ; Zhang, HJ | 1 |
Squire, SB; Vizel, AA; Ziganshina, LE | 1 |
Boom, WH; Charlebois, ED; Daley, CL; Debanne, SM; Dietze, R; Eisenach, KD; Hadad, DJ; Jankus, DD; Johnson, JL; Maciel, E; Palaci, M; Peloquin, CA | 1 |
Squire, SB; Ziganshina, LE | 1 |
Grupper, M; Potasman, I | 1 |
Baba, T; Endo, T; Hagiwara, E; Komatsu, S; Matsumoto, Y; Nishihira, R; Ogura, T; Sato, T; Sekine, A; Shinohara, T; Sogo, Y; Takahashi, H | 1 |
Cynamon, MH; Klemens, SP; Rogge, MC; Sharpe, CA | 1 |
Chirgwin, KD; Cohn, DL; el-Sadr, WM; Hafner, R; Heifets, L; Jones, BE; Klein, O; Matts, JP; Medard, F; Mildvan, D; Nelson, ET; Olibrice, M; Perlman, DC; Salomon, N; Telzak, EE | 1 |
Benson, CA; Chirgwin, KD; El-Sadr, WM; Matts, JP; Nelson, ET; Perlman, DC; Sepkowitz, KA; Telzak, EE | 1 |
Chan, CK; Chau, CH; Lee, J; Leung, CC; Tam, CM; Wong, PC; Yew, WW | 1 |
Hoeppner, V; Marciniuk, D; Peloquin, CA; Reid, J | 1 |
Harada, H; Iwasaki, Y; Minagawa, T; Nagata, K; Nakagawa, M; Nakanishi, M; Natsuhara, A; Takemura, Y | 1 |
7 review(s) available for levofloxacin and Pulmonary Consumption
Article | Year |
---|---|
The treatment effect of Levofloxacin, Moxifloxacin, and Gatifloxacin contained in the conventional therapy regimen for pulmonary tuberculosis: Systematic review and network meta-analysis.
Topics: Antitubercular Agents; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Moxifloxacin; Network Meta-Analysis; Tuberculosis; Tuberculosis, Pulmonary | 2022 |
Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.
Topics: Amikacin; Antitubercular Agents; Capreomycin; Carbapenems; Clofazimine; Diarylquinolines; Drug Therapy, Combination; Fluoroquinolones; Humans; Kanamycin; Levofloxacin; Linezolid; Moxifloxacin; Recurrence; Treatment Failure; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2018 |
The Role of Fluoroquinolones in the Treatment of Tuberculosis in 2019.
Topics: Antitubercular Agents; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Moxifloxacin; Treatment Outcome; Tuberculosis, Pulmonary | 2019 |
Fluoroquinolones for treating tuberculosis (presumed drug-sensitive).
Topics: Antitubercular Agents; Ciprofloxacin; Drug Substitution; Fluoroquinolones; Humans; Levofloxacin; Ofloxacin; Randomized Controlled Trials as Topic; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2013 |
[Pulmonary mycobacteriosis caused by Mycobacterium peregrinum in a young, healthy man].
Topics: Clarithromycin; Drug Therapy, Combination; Ethambutol; Humans; Levofloxacin; Male; Mycobacterium Infections, Nontuberculous; Nontuberculous Mycobacteria; Ofloxacin; Treatment Outcome; Tuberculosis, Pulmonary; Young Adult | 2010 |
Fluoroquinolones for treating tuberculosis.
Topics: Antitubercular Agents; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Ofloxacin; Randomized Controlled Trials as Topic; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2005 |
Fluoroquinolones for treating tuberculosis.
Topics: Antitubercular Agents; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Ofloxacin; Randomized Controlled Trials as Topic; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2008 |
11 trial(s) available for levofloxacin and Pulmonary Consumption
Article | Year |
---|---|
Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Area Under Curve; Aza Compounds; Brazil; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Tuberculosis, Pulmonary | 2008 |
Levofloxacin versus placebo for the treatment of latent tuberculosis among contacts of patients with multidrug-resistant tuberculosis (the VQUIN MDR trial): a protocol for a randomised controlled trial.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Child; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Incidence; Latent Tuberculosis; Levofloxacin; Male; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Vietnam; Young Adult | 2020 |
Efficacy and safety of combined isoniazid-rifampicin-pyrazinamide-levofloxacin dry powder inhaler in treatment of pulmonary tuberculosis: A randomized controlled trial.
Topics: Dry Powder Inhalers; Humans; Isoniazid; Levofloxacin; Powders; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary | 2021 |
An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial.
Topics: Antitubercular Agents; Clinical Protocols; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Humans; Levofloxacin; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Research Design; Time Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2017 |
Population Pharmacokinetic Model and Limited Sampling Strategies for Personalized Dosing of Levofloxacin in Tuberculosis Patients.
Topics: Adult; Antitubercular Agents; Area Under Curve; Bayes Theorem; Drug Dosage Calculations; Drug Monitoring; Female; Humans; Levofloxacin; Male; Middle Aged; Models, Statistical; Mycobacterium tuberculosis; Precision Medicine; Tuberculosis, Pulmonary | 2018 |
Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, m
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Equivalence Trials as Topic; Female; Humans; Levofloxacin; Linezolid; Male; Middle Aged; Multicenter Studies as Topic; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Republic of Korea; Time Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult | 2019 |
Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosis.
Topics: Adult; Aged; Antitubercular Agents; Aza Compounds; Fluoroquinolones; Humans; Levofloxacin; Middle Aged; Moxifloxacin; Prospective Studies; Quinolines; Republic of Korea; Sputum; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult | 2013 |
[Levofloxacin (Tavanic) in complex therapy of tuberculosis].
Topics: Adult; Animals; Antitubercular Agents; Drug Evaluation, Preclinical; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Humans; Levofloxacin; Lung; Male; Mice; Microbial Sensitivity Tests; Middle Aged; Mycobacterium tuberculosis; Ofloxacin; Radiography; Treatment Outcome; Tuberculosis, Pulmonary; Young Adult | 2009 |
[Short-term effect of treatment protocol utilizing levofloxacin, pasiniazide and M. Vaccae on multi- drug resistant pulmonary tuberculosis].
Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Aminosalicylic Acid; Aminosalicylic Acids; Clinical Protocols; Drug Therapy, Combination; Female; Humans; Isoniazid; Levofloxacin; Male; Middle Aged; Ofloxacin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2004 |
Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines; Single-Blind Method; Tuberculosis, Pulmonary | 2006 |
Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Tr
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Female; Humans; Isoniazid; Levofloxacin; Male; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Ofloxacin; Pyrazinamide; Recurrence; Rifampin; Sputum; Treatment Outcome; Tuberculosis, Pulmonary | 1998 |
44 other study(ies) available for levofloxacin and Pulmonary Consumption
Article | Year |
---|---|
Economic Evaluation of Nemonoxacin, Moxifloxacin and Levofloxacin in the Treatment of Early Community-Acquired Pneumonia with Possible Pulmonary Tuberculosis.
Topics: Anti-Bacterial Agents; Community-Acquired Infections; Cost-Benefit Analysis; Fluoroquinolones; Humans; Levofloxacin; Moxifloxacin; Pneumonia; Quinolones; Randomized Controlled Trials as Topic; Tuberculosis, Pulmonary | 2022 |
Effects of Levofloxacin on Blood Lymphocyte Apoptosis in Patients with Pulmonary Tuberculosis: an In Vitro Study.
Topics: Adult; Antitubercular Agents; Apoptosis; Cells, Cultured; fas Receptor; Female; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Mycobacterium tuberculosis; Tuberculosis, Pulmonary | 2019 |
Increased prevalence of levofloxacin-resistant Mycobacterium tuberculosis in China is associated with specific mutations within the gyrA gene.
Topics: Adult; China; DNA Gyrase; Drug Resistance, Bacterial; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Prevalence; Tuberculosis, Pulmonary | 2020 |
Specific gyrA Gene Mutations Correlate with High Prevalence of Discordant Levofloxacin Resistance in Mycobacterium tuberculosis Isolates from Beijing, China.
Topics: Antitubercular Agents; Beijing; DNA Gyrase; DNA, Bacterial; Drug Resistance, Bacterial; Humans; Levofloxacin; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Prevalence; Retrospective Studies; Sequence Analysis, DNA; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2020 |
Gitelman-like syndrome: A rare complication of using aminoglycosides in tuberculosis - A case report.
Topics: Alkalosis; Antitubercular Agents; Capreomycin; Clofazimine; Cycloserine; Deprescriptions; Ethionamide; Gitelman Syndrome; Humans; Hypocalcemia; Hypokalemia; Levofloxacin; Linezolid; Male; Middle Aged; Pyrazinamide; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Water-Electrolyte Imbalance | 2020 |
Efficacy of moxifloxacin combined with levofloxacin in the treatment of drug-resistant tuberculosis.
Topics: Adult; Antibiotics, Antitubercular; Case-Control Studies; Drug Therapy, Combination; Female; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Random Allocation; Time Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult | 2020 |
A recombinant selective drug-resistant M. bovis BCG enhances the bactericidal activity of a second-line anti-tuberculosis regimen.
Topics: Amikacin; Animals; Antigens, Bacterial; Antitubercular Agents; BCG Vaccine; Disease Models, Animal; Drug Resistance, Bacterial; Levofloxacin; Mice, Inbred BALB C; Mice, SCID; Mycobacterium bovis; Mycobacterium tuberculosis; Plasmids; Prothionamide; Pyrazinamide; Tuberculosis, Pulmonary; Vaccines, Synthetic; Virulence | 2021 |
Efficacy of ultra-short course chemotherapy for new smear positive drug susceptible pulmonary tuberculosis: study protocol of a multicenter randomized controlled clinical trial.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Female; Humans; Isoniazid; Levofloxacin; Male; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Rifampin; Treatment Outcome; Tuberculosis, Pulmonary | 2017 |
In Vitro Study of the Modulatory Effects of Levofloxacin and BCG on Secretion of Proinflammatory Cytokines in Infiltrative Pulmonary Tuberculosis.
Topics: Adult; Anti-Bacterial Agents; BCG Vaccine; Case-Control Studies; Drug Combinations; Drug Resistance, Multiple, Bacterial; Female; Humans; Interferon-gamma; Interleukin-12; Interleukin-2; Leukocytes, Mononuclear; Levofloxacin; Male; Middle Aged; Mycobacterium bovis; Mycobacterium tuberculosis; Primary Cell Culture; Tuberculosis, Pulmonary; Tumor Necrosis Factor-alpha | 2018 |
Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis.
Topics: Antitubercular Agents; Ethionamide; Humans; Isoniazid; Levofloxacin; Monte Carlo Method; Mutation; Sputum; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2018 |
Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis.
Topics: Algorithms; Antitubercular Agents; Artificial Intelligence; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Humans; Levofloxacin; Microbial Sensitivity Tests; Monte Carlo Method; Mycobacterium tuberculosis; Sputum; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2018 |
[CLINICAL EFFECTS OF INTRAVENOUSLY ADMINISTERED LEVOFLOXACIN IN PATIENTS WITH PULMONARY TUBERCULOSIS: A RETROSPECTIVE STUDY].
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Female; Humans; Levofloxacin; Male; Retrospective Studies; Tuberculosis, Pulmonary | 2016 |
Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Ciprofloxacin; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Models, Biological; Moxifloxacin; Ofloxacin; Retrospective Studies; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult | 2019 |
Susceptibility testing of extensively drug-resistant and pre-extensively drug-resistant Mycobacterium tuberculosis against levofloxacin, linezolid, and amoxicillin-clavulanate.
Topics: Acetamides; Amoxicillin-Potassium Clavulanate Combination; Antitubercular Agents; Extensively Drug-Resistant Tuberculosis; Humans; Levofloxacin; Linezolid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Ofloxacin; Oxazolidinones; Pakistan; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2013 |
Fluoroquinolones in the treatment of tuberculosis: which is best?
Topics: Aza Compounds; Fluoroquinolones; Humans; Levofloxacin; Moxifloxacin; Quinolines; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2013 |
Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis.
Topics: Adolescent; Adult; Amikacin; Antitubercular Agents; Cycloserine; Ethionamide; Female; Fluoroquinolones; Humans; Kanamycin; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Pyrazinamide; Sputum; Tanzania; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2014 |
[A case of drug-induced hypersensitivity syndrome caused by levofloxacin used for treating pulmonary tuberculosis].
Topics: Adult; Anti-Bacterial Agents; Drug Hypersensitivity; Humans; Levofloxacin; Male; Syndrome; Tuberculosis, Pulmonary | 2014 |
Unsuspected tuberculosis in COPD and use of levofloxacin: diagnostic challenges.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Antitubercular Agents; Body Mass Index; Delayed Diagnosis; Diagnosis, Differential; Drug Therapy, Combination; Female; Humans; Hyperlipidemias; Hypertension; Levofloxacin; Mycobacterium tuberculosis; Pulmonary Disease, Chronic Obstructive; Risk Factors; Smoking; Treatment Outcome; Tuberculosis, Pulmonary | 2014 |
Profile of adverse drug reactions in drug resistant tuberculosis from Punjab.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Arthralgia; Ataxia; Chemical and Drug Induced Liver Injury; Child; Cycloserine; Drug Eruptions; Drug Therapy, Combination; Ethambutol; Ethionamide; Female; Gastrointestinal Diseases; Hearing Loss; Humans; Hypothyroidism; India; Kanamycin; Levofloxacin; Male; Middle Aged; Peripheral Nervous System Diseases; Psychoses, Substance-Induced; Pyrazinamide; Severity of Illness Index; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Vision Disorders; Young Adult | 2014 |
Limited sampling strategy and target attainment analysis for levofloxacin in patients with tuberculosis.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Area Under Curve; Brazil; Humans; Levofloxacin; Microbial Sensitivity Tests; Middle Aged; Models, Biological; Monte Carlo Method; Mycobacterium tuberculosis; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult | 2015 |
Fluoroquinolone use delays tuberculosis treatment despite immediate mycobacteriology study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Community-Acquired Infections; Female; Fluoroquinolones; Follow-Up Studies; Humans; Levofloxacin; Linear Models; Longitudinal Studies; Male; Middle Aged; Moxifloxacin; Multivariate Analysis; Mycobacterium tuberculosis; Ofloxacin; Pneumonia, Bacterial; Taiwan; Tuberculosis, Pulmonary; Young Adult | 2015 |
[Prospects of Levofloxacin Use in Therapy of Patients with Bronchopulmonary Diseases or Skin and Soft Tissue Pyo-Inflammatory Lesions].
Topics: Adult; Anti-Bacterial Agents; Bronchitis; Dose-Response Relationship, Drug; Female; Humans; Levofloxacin; Lung Diseases; Male; Microbial Sensitivity Tests; Middle Aged; Pneumonia, Bacterial; Severity of Illness Index; Skin Diseases, Bacterial; Soft Tissue Infections; Treatment Outcome; Tuberculosis, Pulmonary; Young Adult | 2014 |
Treatment Outcomes with Fluoroquinolone-Containing Regimens for Isoniazid-Resistant Pulmonary Tuberculosis.
Topics: Adult; Aged; Antitubercular Agents; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Isoniazid; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Recurrence; Retrospective Studies; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2016 |
Probable Levofloxacin-associated Secondary Intracranial Hypertension in a Child With Multidrug-resistant Tuberculosis.
Topics: Anti-Bacterial Agents; Child; Female; Humans; Intracranial Hypertension; Levofloxacin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2016 |
Role of gyrB Mutations in Pre-extensively and Extensively Drug-Resistant Tuberculosis in Thai Clinical Isolates.
Topics: Aminopyridines; Antitubercular Agents; Ciprofloxacin; DNA Gyrase; Drug Resistance, Bacterial; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Gatifloxacin; Gene Expression; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Ofloxacin; Thailand; Tuberculosis, Pulmonary | 2016 |
Wild-Type and Non-Wild-Type Mycobacterium tuberculosis MIC Distributions for the Novel Fluoroquinolone Antofloxacin Compared with Those for Ofloxacin, Levofloxacin, and Moxifloxacin.
Topics: Antitubercular Agents; China; DNA Gyrase; Drug Dosage Calculations; Drug Resistance, Bacterial; Fluoroquinolones; Gene Expression; Genotype; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Ofloxacin; Tuberculosis, Pulmonary | 2016 |
[The effect of CD4+ CD25+ regulatory T cell inactivation combined with levofloxacin on murine tuberculosis].
Topics: Animals; Anti-Bacterial Agents; Female; Levofloxacin; Mice; Mice, Inbred C57BL; Ofloxacin; T-Lymphocytes, Regulatory; Tuberculosis, Pulmonary | 2009 |
Mutation characterization of gyrA and gyrB genes in levofloxacin-resistant Mycobacterium tuberculosis clinical isolates from Guangdong Province in China.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; China; DNA Gyrase; DNA, Bacterial; Drug Resistance, Bacterial; Female; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Mutation, Missense; Mycobacterium tuberculosis; Ofloxacin; Sequence Analysis, DNA; Tuberculosis, Pulmonary; Young Adult | 2010 |
[Evaluation of tuberculosis treatment including levofloxacin (LVFX) in cases who could not continue standard regimen].
Topics: Aged; Anti-Bacterial Agents; Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Bacterial; Female; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Tuberculosis; Tuberculosis, Pulmonary | 2011 |
Pulmonary Mycobacterium kyorinense disease showed clinical improvement following combined therapy with clarithromycin and levofloxacin.
Topics: Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Mycobacterium Infections, Nontuberculous; Nontuberculous Mycobacteria; Ofloxacin; Tuberculosis, Pulmonary | 2012 |
Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin.
Topics: Antitubercular Agents; Aza Compounds; DNA Gyrase; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gene Expression Regulation, Bacterial; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Russia; Tuberculosis, Pulmonary | 2013 |
Clinical use of Levofloxacin in the long-term treatment of drug resistant tuberculosis.
Topics: Adult; Aged; Anti-Infective Agents; Female; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Mycobacterium; Ofloxacin; Tuberculosis, Female Genital; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2002 |
[Sensitivity to levofloxacin of Mycobacterium tuberculosis strains with various phenotype isolated from patients with newly diagnosed and chronic tuberculosis].
Topics: Anti-Infective Agents; Chronic Disease; Drug Resistance, Bacterial; Genotype; Humans; Levofloxacin; Mycobacterium tuberculosis; Ofloxacin; Tuberculosis, Pulmonary | 2002 |
[A study on the clinical efficacy of a combination regimen with levofloxacin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis].
Topics: Adolescent; Adult; Antitubercular Agents; Capreomycin; Drug Therapy, Combination; Female; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Ofloxacin; Pyrazinamide; Rifampin; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2003 |
[A preliminary study on the definition of resistant breakpoints of ofloxacin and levofloxacin for Mycobacterium tuberculosis].
Topics: Adolescent; Adult; Aged; Drug Resistance, Bacterial; Female; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Mycobacterium tuberculosis; Ofloxacin; Tuberculosis, Pulmonary | 2004 |
Validation of the use of Middlebrook 7H10 agar, BACTEC MGIT 960, and BACTEC 460 12B media for testing the susceptibility of Mycobacterium tuberculosis to levofloxacin.
Topics: Agar; Anti-Bacterial Agents; Bacteriological Techniques; Culture Media; Drug Resistance, Bacterial; Humans; Levofloxacin; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Ofloxacin; Tuberculosis, Pulmonary | 2004 |
[Clinical observation on treatment of retreated positive tubercle bacillus pneumoconio-tuberculosis with levofloxacin].
Topics: Aged; Anti-Bacterial Agents; Humans; Levofloxacin; Middle Aged; Ofloxacin; Pneumoconiosis; Tuberculosis, Pulmonary | 2004 |
Fluoroquinolones in community-acquired pneumonia when tuberculosis is around: an instructive case.
Topics: Adult; Anti-Bacterial Agents; Community-Acquired Infections; Fluoroquinolones; Humans; Levofloxacin; Male; Mycobacterium tuberculosis; Ofloxacin; Pneumonia, Bacterial; Radiography; Tuberculosis, Pulmonary | 2008 |
[Case of pneumothorax associated with pulmonary Mycobacterium fortuitum infection].
Topics: Adult; Anti-Bacterial Agents; Clarithromycin; Combined Modality Therapy; Drainage; Drug Resistance, Bacterial; Humans; Levofloxacin; Male; Mycobacterium fortuitum; Mycobacterium Infections, Nontuberculous; Ofloxacin; Pneumonectomy; Pneumothorax; Recurrence; Treatment Outcome; Tuberculosis, Pulmonary | 2008 |
Activity of levofloxacin in a murine model of tuberculosis.
Topics: Animals; Antitubercular Agents; Culture Media; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Levofloxacin; Lung; Mice; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Ofloxacin; Quinolones; Spleen; Stereoisomerism; Tuberculosis, Pulmonary | 1994 |
Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG), National Institutes for Hea
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antitubercular Agents; Chi-Square Distribution; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Humans; Levofloxacin; Logistic Models; Male; Microbial Sensitivity Tests; Middle Aged; Ofloxacin; Pilot Projects; Prospective Studies; Risk Factors; Survival Analysis; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; United States | 1999 |
Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens.
Topics: Adult; Aged; Antitubercular Agents; Drug Therapy, Combination; Female; Hong Kong; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Mycobacterium tuberculosis; Ofloxacin; Recurrence; Retrospective Studies; Sputum; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2000 |
Pharmacokinetics of antituberculosis medications delivered via percutaneous gastrojejunostomy tube.
Topics: Adult; Aminosalicylic Acid; Antitubercular Agents; Female; Gastrostomy; Humans; Jejunostomy; Levofloxacin; Ofloxacin; Rifampin; Saskatchewan; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2002 |
[Mycobacterium abscessus infection complicated with diabetes mellitus].
Topics: Adult; Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Cilastatin; Cilastatin, Imipenem Drug Combination; Diabetes Complications; Drug Combinations; Drug Therapy, Combination; Humans; Imipenem; Levofloxacin; Male; Mycobacterium Infections, Nontuberculous; Ofloxacin; Tuberculosis, Pulmonary | 2002 |